Work

Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 Diabetes

Year: 2023

Type: article

Study design: Clinical Trial

Abstract: The t:slim X2 insulin pump with Control-IQ technology (Control-IQ) advanced hybrid closed-loop automated insulin delivery system was evaluated in this prospective single-arm trial. Thirty adults with type 2 diabetes using the Control-IQ system showed substantial glycemic improvement with no increase in hypoglycemia. Mean time in range (70-180 mg/dL) improved 15%, representing an increase of 3.6 hours/day, and mean glucose decreased by 22 mg/dL.

Source: Clinical Diabetes

DOI: 10.2337/cd23-0025

Authors: Carol J. Levy, Dan Raghinaru, Yogish C. Kudva, Keta Pandit, Thomas Blevins, Luis Casaubon, Donna Desjardins, Camilla M. Levister, Grenye O’Malley, Corey Reid, John Lum, Craig Kollman, Roy W. Beck

Institutions: Icahn School of Medicine at Mount Sinai, Jaeb Center for Health Research, Mayo Clinic, Texas Diabetes & Endocrinology

Language: English

Topic: Diabetes Management and Research

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Eli Lilly and Company, AstraZeneca, Insulet Corporation, MannKind Corporation, Dexcom, Tandem Diabetes Care, Novo Nordisk, Abbott Diabetes Care

OpenAlex ID: W4386212186

FWCI: 6.828

Cites: 18

Cited by: 37

Related to: 10